KR100515429B1 - (+)-알파-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올의 에스테르 및 이를 포함하는 약제학적 조성물 - Google Patents
(+)-알파-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올의 에스테르 및 이를 포함하는 약제학적 조성물 Download PDFInfo
- Publication number
- KR100515429B1 KR100515429B1 KR10-2001-7004703A KR20017004703A KR100515429B1 KR 100515429 B1 KR100515429 B1 KR 100515429B1 KR 20017004703 A KR20017004703 A KR 20017004703A KR 100515429 B1 KR100515429 B1 KR 100515429B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- oil
- ethyl
- fluorophenyl
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1998/021608 WO2000021930A1 (fr) | 1998-10-14 | 1998-10-14 | Esters de (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol et leur utilisation comme promedicament de l'antagoniste du recepteur 5ht2a mdl 110,907 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010106517A KR20010106517A (ko) | 2001-11-29 |
KR100515429B1 true KR100515429B1 (ko) | 2005-09-20 |
Family
ID=22268079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-7004703A KR100515429B1 (ko) | 1998-10-14 | 1998-10-14 | (+)-알파-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올의 에스테르 및 이를 포함하는 약제학적 조성물 |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1121345A1 (fr) |
JP (1) | JP2002527422A (fr) |
KR (1) | KR100515429B1 (fr) |
CN (1) | CN1160333C (fr) |
AU (1) | AU1083099A (fr) |
BR (1) | BR9816049A (fr) |
CA (1) | CA2347469C (fr) |
CZ (1) | CZ20011331A3 (fr) |
EA (1) | EA003667B1 (fr) |
EE (1) | EE200100219A (fr) |
HK (1) | HK1039332A1 (fr) |
HR (1) | HRP20010278A2 (fr) |
HU (1) | HUP0200517A3 (fr) |
IL (2) | IL142479A0 (fr) |
NO (1) | NO320417B1 (fr) |
NZ (1) | NZ510631A (fr) |
PL (1) | PL193306B1 (fr) |
SK (1) | SK5082001A3 (fr) |
TR (1) | TR200101047T2 (fr) |
UA (1) | UA57859C2 (fr) |
WO (1) | WO2000021930A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020099076A1 (en) * | 2000-05-25 | 2002-07-25 | Richard Scheyer D. | Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis |
CN102241667B (zh) * | 2010-05-14 | 2013-10-23 | 中国人民解放军军事医学科学院毒物药物研究所 | 1-[(4-羟基哌啶-4基)甲基]吡啶-2(1h)-酮衍生物及其制备方法和用途 |
CN106892897A (zh) * | 2015-12-21 | 2017-06-27 | 上海科胜药物研发有限公司 | 一种羟哌吡酮游离碱新晶型及其制备方法 |
CN106928187A (zh) * | 2015-12-31 | 2017-07-07 | 上海奥博生物医药技术有限公司 | 一种盐酸羟哌吡酮新晶型及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5134149A (en) * | 1990-06-01 | 1992-07-28 | Merrell Dow Pharmaceuticals Inc. | (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
-
1998
- 1998-10-14 NZ NZ510631A patent/NZ510631A/en active IP Right Revival
- 1998-10-14 JP JP2000575839A patent/JP2002527422A/ja active Pending
- 1998-10-14 EE EEP200100219A patent/EE200100219A/xx unknown
- 1998-10-14 EP EP98953458A patent/EP1121345A1/fr not_active Withdrawn
- 1998-10-14 UA UA2001042522A patent/UA57859C2/uk unknown
- 1998-10-14 EA EA200100361A patent/EA003667B1/ru not_active IP Right Cessation
- 1998-10-14 PL PL347318A patent/PL193306B1/pl not_active IP Right Cessation
- 1998-10-14 CZ CZ20011331A patent/CZ20011331A3/cs unknown
- 1998-10-14 CN CNB988142740A patent/CN1160333C/zh not_active Expired - Fee Related
- 1998-10-14 SK SK508-2001A patent/SK5082001A3/sk not_active Application Discontinuation
- 1998-10-14 HU HU0200517A patent/HUP0200517A3/hu unknown
- 1998-10-14 AU AU10830/99A patent/AU1083099A/en not_active Abandoned
- 1998-10-14 TR TR2001/01047T patent/TR200101047T2/xx unknown
- 1998-10-14 WO PCT/US1998/021608 patent/WO2000021930A1/fr active IP Right Grant
- 1998-10-14 CA CA002347469A patent/CA2347469C/fr not_active Expired - Fee Related
- 1998-10-14 KR KR10-2001-7004703A patent/KR100515429B1/ko not_active IP Right Cessation
- 1998-10-14 BR BR9816049-4A patent/BR9816049A/pt not_active Application Discontinuation
- 1998-10-14 IL IL14247998A patent/IL142479A0/xx active IP Right Grant
-
2001
- 2001-04-05 IL IL142479A patent/IL142479A/en not_active IP Right Cessation
- 2001-04-09 NO NO20011805A patent/NO320417B1/no not_active IP Right Cessation
- 2001-04-12 HR HR20010278A patent/HRP20010278A2/hr not_active Application Discontinuation
-
2002
- 2002-02-05 HK HK02100869A patent/HK1039332A1/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5134149A (en) * | 1990-06-01 | 1992-07-28 | Merrell Dow Pharmaceuticals Inc. | (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
Non-Patent Citations (1)
Title |
---|
Modern pharmaceutics, Marcel Dekker, Inc., 3rd edition, pp627-629(1996) * |
Also Published As
Publication number | Publication date |
---|---|
UA57859C2 (uk) | 2003-07-15 |
EA200100361A1 (ru) | 2001-10-22 |
CN1314887A (zh) | 2001-09-26 |
CA2347469C (fr) | 2006-02-28 |
PL347318A1 (en) | 2002-03-25 |
IL142479A0 (en) | 2002-03-10 |
HRP20010278A2 (en) | 2002-06-30 |
CZ20011331A3 (cs) | 2001-08-15 |
CN1160333C (zh) | 2004-08-04 |
AU1083099A (en) | 2000-05-01 |
JP2002527422A (ja) | 2002-08-27 |
PL193306B1 (pl) | 2007-01-31 |
NZ510631A (en) | 2003-07-25 |
NO20011805L (no) | 2001-06-08 |
CA2347469A1 (fr) | 2000-04-20 |
NO20011805D0 (no) | 2001-04-09 |
KR20010106517A (ko) | 2001-11-29 |
NO320417B1 (no) | 2005-12-05 |
BR9816049A (pt) | 2001-07-03 |
HK1039332A1 (en) | 2002-04-19 |
IL142479A (en) | 2006-06-11 |
SK5082001A3 (en) | 2001-11-06 |
EA003667B1 (ru) | 2003-08-28 |
HUP0200517A3 (en) | 2002-12-28 |
HUP0200517A2 (en) | 2002-06-29 |
EE200100219A (et) | 2002-08-15 |
TR200101047T2 (tr) | 2001-08-21 |
EP1121345A1 (fr) | 2001-08-08 |
WO2000021930A1 (fr) | 2000-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09501156A (ja) | 治療法で使用するピペラジン化合物 | |
KR20140081761A (ko) | 메틸페니데이트 프로드러그, 이의 제조 방법 및 사용 방법 | |
US6063793A (en) | Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidi nemethanol | |
EP1289527B1 (fr) | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidine-methanol ou ses prodrogues pour traiter les demences ou les troubles cognitifs | |
TW517048B (en) | Pharmaceutical composition for treating depressive disorders and bipolardisorders comprising (+)-Α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | |
KR100515429B1 (ko) | (+)-알파-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올의 에스테르 및 이를 포함하는 약제학적 조성물 | |
AU2001264842A1 (en) | Use of (+)-alpha -(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4- piperidinemerthanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis | |
BG65206B1 (bg) | Естери на (+)-алфа-(2,3-диметоксифенил)-1-[2-(4-флуорoфенил)етил]-4- пиперидинметанол, метод за тяхното получаване и приложението им като предшественици на 5ht2a рецепторния антагонист mdl 110,907 | |
AU2004200993A1 (en) | Esters of (+)-alpha-(2,3-dimethoxyphenyl-[2-(4-flurophenyl) ethyl]-4-piperidinemethanol and their use as prodrugs of the 5HT2a receptor antagonist MDL 110,907 | |
TW461885B (en) | Esters of (+)-Α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | |
MXPA01003535A (en) | Esters of (+)-alpha-( 2,3- dimethoxyphenyl) -1-[2-(4- fluorophenyl) ethyl]-4- piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 | |
EP1105132B1 (fr) | Utilisation de r(+)-g(a)-(2,3-dimethoxyphenyl)-1- 2-(4-fluorophenyl)ethyl]-4-piperidinemethanol pour le traitement de l'apnee obstructive du sommeil | |
JP5060133B2 (ja) | エステル誘導体及びその医薬用途 | |
PL203533B1 (pl) | Zastosowanie (+)- a-(2,3-dimetoksyfenylo)-1-[2-(4-fluorofenylo)etylo]-4-piperydynometanolu lub jego proleku |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20080908 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |